Tenofovir (hydrate)

Tenofovir hydrate is a nucleotide reverse transcriptase inhibitor to treat HIV and chronic Hepatitis B.

Product Specifications

CAS Number

[206184-49-8]

Product Name Alternative

GS 1278 (hydrate) ; PMPA (hydrate)

UNSPSC

12352005

Hazard Statement

H301, H312, H330, H410

Target

HIV; Reverse Transcriptase

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection; Cancer

Assay Protocol

https://www.medchemexpress.com/tenofovir-hydrate.html

Purity

99.53

Solubility

DMSO : ≥ 6 mg/mL

Smiles

C[C@@H](OCP(O)(O)=O)CN1C=NC2=C(N)N=CN=C12.O

Molecular Formula

C9H16N5O5P

Molecular Weight

305.23

Precautions

H301, H312, H330, H410

References & Citations

[1]Murphy RA, et al. Establishment of HK-2 Cells as a Relevant Model to Study Tenofovir-Induced Cytotoxicity. Int J Mol Sci. 2017 Mar 1;18 (3) .|[2]Musumeci G, et al. M48U1 and Tenofovir combination synergistically inhibits HIV infection in activated PBMCs and human cervicovaginal histocultures. Sci Rep. 2017 Feb 1;7:41018.|[3]Wahl A, et al. Predicting HIV Pre-exposure Prophylaxis Efficacy for Women using a Preclinical Pharmacokinetic-Pharmacodynamic In Vivo Model. Sci Rep. 2017 Feb 1;7:41098.|[4]Menne S, Cote PJ, Korba BE, Antiviral effect of oral administration of tenofovir disoproxil fumarate in woodchucks with chronic woodchuck hepatitis virus infection. Antimicrob Agents Chemother. 2005 Jul;49 (7) :2720-8.